Drug Profile
Vicagrel - China Pharmaceutical University/Jiangsu Vcare Pharmatech
Latest Information Update: 08 Jan 2024
Price :
$50
*
At a glance
- Originator China Pharmaceutical University; Jiangsu Vcare Pharmatech
- Developer Jiangsu Vcare Pharmatech
- Class 2 ring heterocyclic compounds; Antiplatelets; Antithrombotics; Cardiovascular therapies; Small molecules; Thienopyridines; Vascular disorder therapies
- Mechanism of Action Platelet ADP receptor antagonists; Purinoceptor P2Y12 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preregistration Acute coronary syndromes; Peripheral arterial disorders; Stroke
- Phase II Thrombosis